{
    "nctId": "NCT00118508",
    "briefTitle": "The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)",
    "officialTitle": "The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)",
    "overallStatus": "COMPLETED",
    "conditions": "Osteoporosis",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 87,
    "primaryOutcomeMeasure": "That bone loss, as determined through BMD every six months, will be prevented at clinically relevant sites, such as the hip & spine, through the use of bisphosphonate therapy in study subjects.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pre- and newly postmenopausal (up to 8 years) women ages 18 and older\n* Breast cancer treated with chemotherapeutic agents, with or without tamoxifen/aromatase inhibitors\n* Negative pregnancy test\n\nExclusion Criteria:\n\n* Stage 4 breast cancer\n* Any illness or medications known to affect bone metabolism\n* History of osteoporosis or history of vertebral or hip fractures\n* Kidney stones in the past 5 years\n* Active peptic ulcer disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}